Maria Diaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maria Diaz has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Robert J. Young
From the Department of Medical Physics (D.G.S.), Radiology (A.N., B.M.-P., O.Y., J.S., Akash S., V.H., Atin S., L.K., S.H., N.S., M.T.S., J.T., R.Y., A.H., H.S., J.N.S.), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
18 shared publications - Ankush Bhatia
Neurology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA
17 shared publications - Anna Skakodub
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
17 shared publications - Anne S. Reiner
Memorial Sloan Kettering Cancer Center, New York, New York, USA
17 shared publications - Henry Walch
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
17 shared publications - Ingo K. Mellinghoff
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, USA
17 shared publications
Latest Publications
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S1. Alterations in Molecular-Grade High Group IDH-mutant Gliomas.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S1. Alterations in Molecular-Grade High Group IDH-mutant Gliomas.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S1. Alterations in Molecular-Grade High Group IDH-mutant Gliomas.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S1. Alterations in Molecular-Grade High Group IDH-mutant Gliomas.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S3. Baseline Radiological Characteristics Stratified by Molecular Grade.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S3. Baseline Radiological Characteristics Stratified by Molecular Grade.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S2. Baseline Radiological Characteristics Overall and Stratified by 1p19q Status.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S2. Baseline Radiological Characteristics Overall and Stratified by 1p19q Status.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Purpose:Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain tumors characterized by a slow-growing phase over several years followed by a rapid-growing malignant phase. We hypothesized that tumor volume growth rate (TVGR) on MRI may act as an earlier measure of clinical benefit during the active surveillance period.Experimental Design:We integrated three-dimensional volumetric measurements with clinical, radiologic, and molecular data in a retrospective cohort of IDH-mt gliomas that were observed after surgical resection in order to understand tumor growth kinetics and the impact of molecular genetics.Results:Using log-linear mixed modeling, the entire cohort (n = 128) had a continuous %TVGR per 6 months of 10.46% [95% confidence interval (CI), 9.11%–11.83%] and a doubling time of 3.5 years (95% CI, 3.10–3.98). High molecular grade IDH-mt gliomas, defined by the presence of homozygous deletion of CDKN2A/B, had %TVGR per 6 months of 19.17% (95% CI, 15.57%–22.89%) which was significantly different from low molecular grade IDH-mt gliomas with a growth rate per 6 months of 9.54% (95% CI, 7.32%–11.80%; P < 0.0001). Using joint modeling to comodel the longitudinal course of TVGR and overall survival, we found each one natural logarithm tumor volume increase resulted in more than a 3-fold increase in risk of death (HR = 3.83; 95% CI, 2.32–6.30; P < 0.0001).Conclusions:TVGR may be used as an earlier measure of clinical benefit and correlates well with the WHO 2021 molecular classification of gliomas and survival. Incorporation of TVGR as a surrogate endpoint into future prospective studies of IDH-mt gliomas may accelerate drug development.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Purpose:Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain tumors characterized by a slow-growing phase over several years followed by a rapid-growing malignant phase. We hypothesized that tumor volume growth rate (TVGR) on MRI may act as an earlier measure of clinical benefit during the active surveillance period.Experimental Design:We integrated three-dimensional volumetric measurements with clinical, radiologic, and molecular data in a retrospective cohort of IDH-mt gliomas that were observed after surgical resection in order to understand tumor growth kinetics and the impact of molecular genetics.Results:Using log-linear mixed modeling, the entire cohort (n = 128) had a continuous %TVGR per 6 months of 10.46% [95% confidence interval (CI), 9.11%–11.83%] and a doubling time of 3.5 years (95% CI, 3.10–3.98). High molecular grade IDH-mt gliomas, defined by the presence of homozygous deletion of CDKN2A/B, had %TVGR per 6 months of 19.17% (95% CI, 15.57%–22.89%) which was significantly different from low molecular grade IDH-mt gliomas with a growth rate per 6 months of 9.54% (95% CI, 7.32%–11.80%; P < 0.0001). Using joint modeling to comodel the longitudinal course of TVGR and overall survival, we found each one natural logarithm tumor volume increase resulted in more than a 3-fold increase in risk of death (HR = 3.83; 95% CI, 2.32–6.30; P < 0.0001).Conclusions:TVGR may be used as an earlier measure of clinical benefit and correlates well with the WHO 2021 molecular classification of gliomas and survival. Incorporation of TVGR as a surrogate endpoint into future prospective studies of IDH-mt gliomas may accelerate drug development.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S3. Baseline Radiological Characteristics Stratified by Molecular Grade.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S3. Baseline Radiological Characteristics Stratified by Molecular Grade.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S3. Next-Intervention-Free Survival and overall survival.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S3. Next-Intervention-Free Survival and overall survival.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S4. Clinical Characteristics and Tumor Volume Growth During Active Surveillance.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S4. Clinical Characteristics and Tumor Volume Growth During Active Surveillance.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S1. Somatic genomic alterations in the cohort of IDH-mutant gliomas.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Figure S1. Somatic genomic alterations in the cohort of IDH-mutant gliomas.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S2. Baseline Radiological Characteristics Overall and Stratified by 1p19q Status.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Supplementary Table S2. Baseline Radiological Characteristics Overall and Stratified by 1p19q Status.